These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37909264)

  • 1. Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis.
    Takeuchi T; Chino Y; Mano Y; Kawanishi M; Sato Y; Uchida S; Tanaka Y
    J Clin Pharmacol; 2024 Apr; 64(4):418-427. PubMed ID: 37909264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY
    Takeuchi T; Chino Y; Kawanishi M; Nakanishi M; Watase H; Mano Y; Sato Y; Uchida S; Tanaka Y
    Arthritis Res Ther; 2023 Apr; 25(1):60. PubMed ID: 37055803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis.
    Tanaka Y
    Expert Opin Biol Ther; 2023; 23(7):579-587. PubMed ID: 37431762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora
    Kawanishi M; Fujii Y
    Nihon Yakurigaku Zasshi; 2023; 158(6):490-499. PubMed ID: 37914330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):875-882. PubMed ID: 36201360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ozoralizumab, a Humanized Anti-TNFα NANOBODY
    Ishiwatari-Ogata C; Kyuuma M; Ogata H; Yamakawa M; Iwata K; Ochi M; Hori M; Miyata N; Fujii Y
    Front Immunol; 2022; 13():853008. PubMed ID: 35273620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).
    Tanaka Y; Kawanishi M; Nakanishi M; Yamasaki H; Takeuchi T
    Mod Rheumatol; 2023 Aug; 33(5):883-890. PubMed ID: 36197757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY
    Kyuuma M; Kaku A; Mishima-Tsumagari C; Ogawa B; Endo M; Tamura Y; Ishikura KI; Mima M; Nakanishi Y; Fujii Y
    Front Immunol; 2023; 14():1149874. PubMed ID: 37122706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
    Takeuchi T; Kawanishi M; Nakanishi M; Yamasaki H; Tanaka Y
    Arthritis Rheumatol; 2022 Nov; 74(11):1776-1785. PubMed ID: 35729713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor.
    Takeuchi T
    Mod Rheumatol; 2023 Nov; 33(6):1059-1067. PubMed ID: 37185766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
    Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
    J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ozoralizumab: First Approval.
    Keam SJ
    Drugs; 2023 Jan; 83(1):87-92. PubMed ID: 36509938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel anti-TNF-α drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis.
    Oyama S; Ebina K; Etani Y; Hirao M; Kyuuma M; Fujii Y; Iwata K; Ogawa B; Hasegawa T; Kawano S; Nakanishi Y; Okada S; Nakata K
    Sci Rep; 2022 Oct; 12(1):18102. PubMed ID: 36302840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Xu Y; Hu C; Zhuang Y; Hsu B; Xu Z; Zhou H
    J Clin Pharmacol; 2018 Jul; 58(7):939-951. PubMed ID: 29578578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.